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Abstract 
Background: An effective malaria transmission‑blocking vaccine may play an important role in malaria elimination 
efforts, and a robust biological assay is essential for its development. The standard membrane‑feeding assay (SMFA) 
for Plasmodium falciparum infection of mosquitoes is considered a “gold standard” assay to measure transmission‑
blocking activity of test antibodies, and has been utilized widely in both non‑clinical and clinical studies. While several 
studies have discussed the inherent variability of SMFA within a study group, there has been no assessment of inter‑
laboratory variation. Therefore, there is currently no assurance that SMFA results are comparable between different 
studies.
Methods: Mouse anti‑Pfs25 monoclonal antibody (mAb, 4B7 mAb), rat anti‑Pfs48/45 mAb (85RF45.1 mAb) and a 
human polyclonal antibody (pAb) collected from a malaria‑exposed adult were tested at the same concentrations 
(6–94 μg/mL for 4B7, 1.2–31.3 μg/mL for 85RF45.1 and 23–630 μg/mL for human pAb) in two laboratories following 
their own standardized SMFA protocols. The mAbs and pAb, previously shown to have strong inhibition activities in 
the SMFA, were tested at three or four concentrations in two or three independent assays in each laboratory, and 
percent inhibition in mean oocyst intensity relative to a control in the same feed was determined in each feeding 
experiment.
Results: Both monoclonal and polyclonal antibodies dose‑dependently reduced oocyst intensity in all experiments 
performed at the two test sites. In both laboratories, the inter‑assay variability in percent inhibition in oocyst intensity 
decreased at higher levels of inhibition, regardless of which antibody was tested. At antibody concentrations that led 
to a >80 % reduction in oocyst numbers, the inter‑laboratory variations were in the same range compared with the 
inter‑assay variation observed within a single laboratory, and the differences in best estimates from multiple feeds 
between the two laboratories were <5 percentage points.
Conclusions: This study confirms previous reports that the precision of the SMFA increases with increasing percent 
inhibition. Moreover, the variation between the two laboratories is not greater than the variation observed within a 
laboratory. The findings of this study provide guidance for comparison of SMFA data from different laboratories.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Malaria mortality and morbidity have declined signifi-
cantly in many parts of the world in the last 2 decades 
[1]. Despite this achievement, the World Health Organi-
zation estimated that there were still 438,000 deaths due 
to malaria in 2015, and that  ~70  % of deaths occurred 
in children less than 5  years old [1]. Recently, Bhatt 
et al. estimated that 663 million clinical cases have been 
averted by malaria interventions from 2000 to 2015 in 
sub-Saharan Africa, largely as a result of insecticide-
treated bed nets and indoor residual spraying [2]. How-
ever, the emergence of resistance in Anopheles vectors 
to current insecticides, and shifting behavioural pat-
terns among vector groups are a great concern for future 
malaria control [3]. In addition, the spread of resist-
ance to artemisinin-based combination therapy among 
Southeast Asian parasite strains have been reported [4]. 
Novel interventions are, therefore, important extensions 
to the current range of control tools, and may be neces-
sary to achieve elimination in many currently endemic 
areas [5]. Transmission-blocking vaccines that inter-
rupt human-to-mosquito transmission by targeting the 
sexual, sporogonic, or mosquito stages of the parasite 
are called SSM-VIMT. SSM-VIMT have the potential to 
reduce malaria transmission from humans to mosquitoes 
for whole populations, and could be an important sup-
plement to traditional controls in countries striving for 
malaria elimination [6–8].
SSM-VIMT are designed to elicit anti-parasite or anti-
mosquito antibodies in vaccinees, and the antibodies 
block parasite development in the mosquito vector when 
ingested with gametocytes: the sexual-stage, transmissi-
ble form of the malaria parasite. While several different 
assays can be applied for SSM-VIMT development [9], 
the standard membrane-feeding assay (SMFA) is con-
sidered the “gold standard” for determining the impact 
of test factors on gametocyte infectivity to mosquitoes 
(either measured by a reduction in oocyst intensity or in 
prevalence of infected mosquitoes). The SMFA has broad 
utility, and has been employed to evaluate the function-
ality of vaccine or whole-parasite induced antibodies in 
animal studies and human clinical trials [7, 8, 10–12], as 
well as antibodies induced by natural exposure to malaria 
infection in endemic settings [13–16]. Furthermore, 
increasing interest in transmission-blocking drugs has 
made the SMFA a useful assay for malaria drug develop-
ment [17–19].
While there are variations in SMFA methodology 
among different investigators, the assay is generally 
conducted by feeding a blood meal containing a mix-
ture of cultured Plasmodium falciparum gametocytes 
and test (or control) antibodies to Anopheles mosquitoes 
through a membrane-feeding apparatus. Approximately 
1 week later mosquitoes from the test and control groups 
are examined to enumerate the oocyst-forms of para-
sites that, if present, can be visualized in the epithelium 
of the mosquito’s midgut by mercury-bromide staining. 
A recent study qualified SMFA following the Interna-
tional Conference on Harmonisation (ICH) Harmonised 
Tripartite Guideline Q2(R1) using an anti-Pfs25 mono-
clonal antibody (mAb) with a single protocol [20]. The 
study concluded that the range (the levels of transmis-
sion-blocking activity in which the analytical procedure 
has a suitable level of precision and linearity) of SMFA 
performed with their method was when there was more 
than ~80 % inhibition in oocyst intensity. However, there 
have been no direct studies, which assess inter-laboratory 
variation in % inhibition in SMFA.
Modern vaccine development relies heavily on col-
laborative research efforts and product development 
partnerships that involve multiple laboratories around 
the world [21]. Though highly standardized SMFAs have 
been performed in separate facilities, there is no assur-
ance that SMFA data derived from experiments per-
formed by different investigators are comparable. To 
enable such comparison, SMFA performance using the 
same test antibodies was assessed at two laboratories, 
TropIQ Health Sciences (TropIQ, using methodologies 
adapted from Radboud University Medical Center [Rad-
boudumc], Nijmegen, The Netherlands) and the Labo-
ratory of Malaria and Vector Research (LMVR, USA). 
Variation between the laboratories was assessed using 
a mouse mAb, a rat mAb, and human polyclonal anti-
body (pAb), all tested at several concentrations in two or 
three independent assays. When conducted under con-
trolled conditions in different laboratories, the SMFA 
can provide informative comparable data for SSM-VIMT 
development.
Methods
Test materials
The details of mouse 4B7 (anti-Pfs25) mAb [22] and rat 
85RF45.1 (anti-Pfs48/45) mAb [23] used in this study 
have been described previously. A protein G purified 
normal mouse IgG was used as the negative control for 
SMFA with 4B7 and 85RF45.1 mAbs, and the details of 
IgG preparation were described previously [20]. Human 
serum was sourced from a malaria-exposed Dutch 
Keywords: Plasmodium falciparum, Gametocyte, Oocyst, Transmission, Anopheles, Mosquito, Vaccine, SSM‑VIMT
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expatriate with well documented antibody-mediated 
transmission-blocking activity, who gave verbal, but not 
written informed consent for his blood sample to be used 
for malaria research [24]. A pool of negative human sera 
was obtained from malaria-naive Dutch adults at San-
quin blood bank (Nijmegen, the Netherlands). From the 
positive and negative human sera, total IgGs were puri-
fied according to the manufacturer’s instructions using a 
GE Healthcare AB Spintrap purification kit (Little Chal-
font, United Kingdom) at TropIQ/Radboudumc.
SMFA
The standardized methodology for performing the SMFA 
at LMVR has been described previously [20]. The meth-
odology at TropIQ has also been described elsewhere 
and is based on that developed at Radboudumc and uses 
mosquitoes from Radboudumc facilities [25]. The TropIQ 
method differs from the Radboudumc method in that the 
quality of the gametocyte culture is assessed based on 
microscopic examination of male exflagellation instead 
of determination of ookinete formation in a sample 
that is fed to mosquitoes a day before the actual feed. In 
addition, the TropIQ method uses a different pipetting 
scheme that uses pooled reagents/parasites where possi-
ble as opposed to preparing each blood meal individually. 
The differences between the LMVR and TropIQ assays 
are summarized in Table 1. In this study, all SMFAs were 
conducted with P. falciparum NF54 line parasites and 
Anopheles stephensi mosquitoes that were propagated 
independently in the two laboratories. Oocyst counts 
were performed microscopically. Throughout the text, 
antibody concentration is expressed relative to the liquid 
phase in a feeder, i.e., serum and buffer, and does not take 
into consideration the volume taken up by the red blood 
cells.
Statistical analysis
Two different readouts have been widely used to express 
SMFA results, % inhibition in mean oocyst intensity 
(%TRA) and % inhibition in prevalence of infected mos-
quitoes (%TBA). It was decided to use %TRA for this 
analysis, since %TBA is dependent on the mean oocyst 
Table 1 Details of SMFA methods
a Haematocrit
b Add lyophilized human serum to make the liquid volume for test antibody to be 100 % human serum
c Final haematocrit in a feeder
d Final stage V gametocytaemia in a feeder
e Not determined
Parameters LMVR TropIQ
All tests mAbs Human pAb
Gametocyte culture
 Flask 25 or 75 cm2 flask Tipper culture flask
 Htca (%) 5.0 5.0 5.0
Feeding
 Total volume (μL) 260 270 1200
 Liquid volume (μL) 160 119 696
 Liquid contents 100 μL of human serum plus  
60 μL of sample in 1xPBS
119 μL of human serumb 696 μL of human 
serumb
 Htcc (%) 38.5 55.9 42.0
 Stage V gametocyted (%) 0.1–0.2 0.1–1.0 NDe
 Starving mosquitoes (h) 18–21 1 1
 Time of feed (min) 20 10 10
 Elimination of unfed mosquitoes  
from analysis
Only mosquitoes with eggs at the  
time of dissection are analysed
One hour after feeding, fully fed mosquitoes are 
selected transported to a bigger cage
Dissection
 Days post feed (day) 8 8 8
 Number of mosquitoes 20 20 30
Quality control
 Pre‑feeding >0.5 % of stage V gametocytaemia  
and >800/mL of exflagellating centres  
in the undiluted culture
Positive for male exflagellating gametocytes
 Post‑feeding >4 oocysts/midgut in the assay controls >70 % infected mosquitoes in the assay controls
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count in the control mosquitoes, and can only be reason-
ably estimated from the control mean and %TRA [26]. 
%TRA was calculated as: 100 ×  {1 −  (mean number of 
oocysts in the test group)/(mean number of oocysts in 
the control groups)}. Percent inhibition of a test sample 
was always calculated against a control sample (either 
normal mouse antibody or normal human antibody) 
examined in the same feeding experiment. In each labo-
ratory, the same samples were tested in 2 or 3 independ-
ent assays at the same concentrations. The best estimate 
and 95 % confidence intervals (95 % CIs) of %TRA from 
the multiple feeding experiments for each test antibody 
at each concentration in each laboratory were calcu-
lated using a negative binomial model with zero infla-
tion model, as described previously [20]. To examine 
inter-laboratory variability, a multiple linear regression 
was utilized. Previous studies have shown that when the 
dose of antibody is plotted on a square root scale against 
inhibitory activity, specifically log-transformed mean 
oocyst ratio between test and control, SMFA data can be 
approximated to a linear regression [11, 20, 27]. There-
fore, the same transformation was performed for the 
linear regression analysis. Since 100  %TRA data points 
were outside of linear range (i.e., log-transformed values 
became infinity), such points were excluded. The dose of 
antibody, laboratory of performing SMFA and the inter-
action of the two were used as explanatory variables. For 
the IC50 estimation, logistic regression was performed 
as described [19]. Briefly, oocyst counts from individual 
mosquitoes exposed to varying concentrations of test 
antibody were fitted to a Hill equation using Maximum 
Likelihood Estimation to find the best fit. All statistical 
tests were performed using R (R Foundation for Statis-
tical Computing, Vienna, Austria), JMP12 (SAS Insti-
tute, Inc., Cary, NC) and p values <0.05 were considered 
significant.
Results
Similar correlations between mean oocysts and standard 
deviations or prevalence between the two laboratories
Several groups have reported that the distribution of 
oocyst numbers is explained well by a (zero-inflated) neg-
ative binomial model [20, 25, 28, 29]. TropIQ and LMVR 
use slightly different SMFA protocols (Table 1). To assess 
whether the data from the two laboratories show an over-
all similar distribution, the correlations: (1) between the 
mean number of oocysts in the mosquito and the stand-
ard deviation (SD) of the mean oocyst number, and (2) 
between mean oocyst number and the prevalence of 
infected mosquitoes (the fraction of mosquitoes con-
taining any number of oocysts) were evaluated. For this 
purpose, LMVR historical data (including data generated 
outside of the present study) and TropIQ data (generated 
in the present study) were compared. For each “Con-
tainer of Mosquitoes” (COM), the mean oocysts, the SD 
and the prevalence of infected mosquitoes were calcu-
lated. Throughout the paper, COM refers to a group of 
mosquitoes (~20 to 30 mosquitoes), which were housed 
in the same container and were fed the using same feeder 
with the same final mixture of gametocyte cultures and 
control/test antibodies. As shown in Fig.  1, the correla-
tions observed in the TropIQ data generated in this study 
overlap with those observed in LMVR historical data. As 
there are no indications for a divergent data structure, 
the zero-inflated negative binomial model previously 
described by LMVR [20] was used to analyse the data 
sets from both laboratories. Interestingly, a similar cor-
relation between mean oocysts and prevalence was also 
observed in SMFA with Plasmodium berghei parasites 
[29].
SMFA comparison with mAbs
A mouse 4B7 (anti-Pfs25) mAb, which had been tested in 
many independent assays at LMVR, was tested at TropIQ 
at three different concentrations in two independent 
assays (Fig. 2). Inter-assay variation was calculated as the 
variation between different assay repeats of a single anti-
body condition within each laboratory, while inter-lab-
oratory variation is given as the difference in inhibition 
for all assay repeats of a given condition between labora-
tories. At LMVR, the best estimates and the 95 % CIs of 
%TRA by 4B7 mAb were 25 (95 % CI −6 to 47: n = 9), 71 
(65 to 76: n = 35) and 96 (96 to 97: n = 181) at 6, 23 and 
94 μg/mL, respectively. The best estimates and the 95 % 
CI of TropIQ data were 20 (−76 to 65), 72 (38 to 89) and 
98 (94 to 99) at 6, 23 and 94 μg/mL, respectively (n = 2 
a b
Fig. 1 Strong correlations between mean oocysts and the standard 
deviation or the prevalence at both LMVR and TropIQ. For each 
COM, mean number of oocysts, the standard deviation a and the 
prevalence of infected mosquitoes b were calculated. Each point 
represents the data from a single COM. LMVR data include all COMs 
examined at LMVR in the last 5 years (n = 3014), and TropIQ data 
include only COMs used in this study (n = 33)
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at each concentration). In agreement with previous work 
[20], inter-assay variation decreased with increasing 
activity of the antibody, as indicated by the smaller con-
fidence intervals at higher %TRA, in both laboratories. 
Since 4B7 mAb was tested in many more feeding experi-
ments at LMVR, the 95 % CIs at LMVR were smaller. In 
addition, fewer mean oocysts in the controls of the par-
ticular TropIQ feeds might partially contribute to the 
larger 95 % CIs. Nevertheless, the difference between the 
two laboratories in the best estimate of %TRA was less 
than 2 % points at 94 μg/mL.
Rat 85RF45.1 (anti-Pfs48/45) mAb was next tested at 
four different concentrations in two independent assays 
in both laboratories. The mAb dose-dependently inhib-
ited oocyst formation. At higher concentrations of the 
mAb (i.e. 10.4 and 31.3  μg/mL), the %TRA observed 
for replicate experiments within labs and between labs 
were very comparable (Fig.  3). At lower concentrations, 
the observed %TRA diverged more between replicate 
experiments, both within and between laboratories (i.e. 
concentrations of 1.2 and 3.5  μg/mL). Since four differ-
ent doses of mAb were tested in each feed, and the same 
number of feeds were conducted in each laboratory, fur-
ther analysis was performed to determine the effects of 
dose and laboratory on inhibition. In a multiple linear 
regression analysis, dose of 85RF45.1 mAb, laboratory, 
and the interaction of the two were used as explanatory 
variables. The overall fit to the linear regression model 
was R2 = 0.73. While there was a significant effect of dose 
(p =  0.032), the laboratory (p =  0.427) and interaction 
term (dose and laboratory, p = 0.659) had no significant 
impact. The effect of dose on oocyst intensity was fur-
ther investigated by fitting the data to a Hill equation (see 
Additional file  1). Resulting IC50 estimates (the concen-
tration at which the mAb shows 50 % inhibition) were 1.2 
and 8.8 µg/mL [feed 1 (F1) and feed 2 (F2) experiments] 
for data generated at LMVR and 3.4 and 2.5 µg/mL (F1 
and F2) for data generated at TropIQ.
SMFA comparison with human polyclonal antibody
Lastly, a human pAb, which has shown a strong inhibi-
tory activity in SMFA, was tested at four concentra-
tions (23, 70, 210 and 630 μg/mL) in three independent 
assays in each laboratory (Fig. 4). At 630 μg/mL, the pAb 
showed a strong and reproducible  %TRA in both labo-
ratories (best estimate of 96.6 %TRA at LMVR and 99.6 
at TropIQ), and there was a dose-dependent reduction in 
oocyst numbers observed in each feeding experiment. As 
with the experiments using the rodent mAbs, inter-assay 
variation was larger at lower inhibitions. When a mul-
tiple linear regression analysis was performed using all 
Fig. 2 SMFA comparison with 4B7 mAb. In LMVR, mouse 4B7 mAb 
was tested at 6 (n = 9), 23 (n = 35) and 94 (n = 181) μg/mL in multi‑
ple feeding experiments. At TropIQ, 4B7 mAb was tested at the same 
concentrations in two independent feeding assays. Individual feeding 
data and the best estimate of %TRA (with the 95 % CIs) from multiple 
feeds (LMVR‑Comb or TropIQ‑Comb) are shown. Average oocysts in 
a negative control antibody (normal mouse IgG) of TropIQ‑feed 1(F1) 
and ‑feed 2(F2) experiments were 6.5 and 4.2, respectively. Average 
oocysts in negative control antibodies for LMVR experiments was 
21.6 (SD = 18.5)
Fig. 3 SMFA comparison with 85RF45.1 mAb. In both laboratories, 
rat 85RF45.1 mAb was tested at 1.2, 3.5, 10.4 and 31.3 μg/mL in two 
feeding experiments (F1 and F2). The individual data and the best 
estimate with 95 % CIs from the two feeds (LMVR‑Comb or TropIQ‑
Comb) at each concentration of 85RF45.1 mAb are shown. Average 
oocysts in a negative control antibody (normal mouse IgG) of LMVR‑
F1, ‑F2, TropIQ‑F1, and ‑F2 experiments were 7.8, 61.6, 6.5 and 4.2, 
respectively
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four pAb concentrations (overall fit was R2 = 0.79), there 
was a significant effect of dose (p < 0.0001) on inhibition, 
but the effect of the laboratory (p = 0.232) and interac-
tion term (dose and laboratory, p = 0.206) were not sig-
nificant. Fitting the data to a Hill equation revealed IC50 
estimates of 126, 329 and 158 μg/mL at LMVR, and 64, 
66 and 198 μg/mL at TropIQ (see Additional file 2).
Discussion
This is the first study to evaluate inter-laboratory vari-
ation of the SMFA, the “gold standard” assay for Plas-
modium gametocyte infectivity, using a range of 
transmission reducing test antibodies (mouse and rat 
mAbs, and human pAb). In this study, regardless of 
antibody type or the targets recognized by the antibod-
ies tested, inter-assay and inter-laboratory variation 
decreased with increasing inhibition of oocyst formation. 
Conversely, variation became larger in both laborato-
ries with decreasing percent inhibition. These results are 
in line with previous observations that precision of the 
SMFA increases with higher percentage reduction, and 
that levels of inhibition below 80 % need to be interpreted 
with caution when low numbers of replicate data are 
available [29]. Across the range of antibodies and concen-
tration tested, inter-laboratory variation did not appear 
to be greater than the inter-assay variation observed 
within a laboratory. However, inter-assay variations were 
larger at lower levels of inhibition, therefore, it is possible 
that inter-laboratory variations could not be detected, if 
any, in the lower range. Since the error in %TRA estimate 
changes gradually (larger error with lower %TRA) as 
expected from the zero-inflated negative binomial model 
[20] and shown in this study, it may be difficult to estab-
lish a specific level of %TRA at which the inter-assay or 
inter-laboratory variations are acceptable in all situations. 
For example, in assessing samples from a clinical study it 
may be justifiable to set up more stringent criteria than 
that in a novel candidate discovery study. However, this 
study showed that at antibody concentrations that led to 
a >80 % reduction in oocyst numbers, the differences in 
best estimates of %TRA from multiple feeds between the 
two laboratories were less than 5 % points.
The SMFA is critical to SSM-VIMT development and 
there are preceding studies that provide several guidances 
to optimize intra-laboratory precision when perform-
ing SMFA. Medley et al. suggested that at least 50 mos-
quitoes (ideally 100) need to be dissected to accurately 
assess transmission-blocking activity [28]. Another study 
by van der Kolk et al. concluded that if all samples are not 
tested in a single experiment, data from different assays 
should be compared only when the mean intensity in the 
control is at least 35 oocysts per mosquito [13]. Churcher 
et  al. simulated how many mosquitoes were required 
for dissection per feed to ensure that a reported percent 
inhibition value had within 10 % error from the true effi-
cacy [29]. For example, if the mean oocyst number in the 
control is 5, it is estimated that ~200 mosquitoes need to 
be dissected to accurately report 80 % inhibition, whereas 
if the mean oocyst number is 100, approximately 50 mos-
quitoes need to be dissected.
At the present time, it is practically challenging and 
resource intensive to only regard SMFA experiments 
with a mean control oocyst intensity of 35 oocysts per 
mosquito as valid. In terms of the mosquito supply and 
maintenance, amount of test material required, and the 
labor intensiveness of dissection, it is also impractical 
to routinely perform the SMFA with 200 mosquitoes 
per COM (to be ready if the mean oocysts number in 
the control were to be 5 oocysts), To some degree, these 
difficulties can be overcome using one of several modi-
fied methods recently published [19, 25, 30], i.e. higher 
throughput SMFA using transgenic parasites that allow 
(semi-) automated detection of infection and may elimi-
nate the need for mosquito dissection. However, the 
modified assays are not necessarily applied to all labo-
ratories at present. Therefore, the comparison study was 
conducted using the SMFA methods usually performed 
in many laboratories; i.e. by dissection of 20–30 mos-
quitoes per feed. With these study conditions, SMFA 
Fig. 4 SMFA comparison with positive human pAb. In both labora‑
tories, test human pAb was tested at 23, 70, 10.4, 210 and 630 μg/mL 
in three feeding experiments (F1, F2 and F3). The individual data and 
the best estimate with 95 % CIs from the three feeds (LMVR‑Comb or 
TropIQ‑Comb) at each concentration of test human pAb are shown. 
Average oocysts in the negative control (normal human IgG) of 
LMVR‑F1, ‑F2, ‑F3, TropIQ‑F1, ‑F2 and ‑F3 experiments were 3.9, 60.3, 
14.0, 16.9, 4.3 and 5.9, respectively
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showed high precision only at higher levels of inhibition. 
The modifications of the assay discussed above (e.g., dis-
secting 200 mosquitoes per COM, only utilizing SMFA 
data when mean control oocyst intensity is >35) should 
expand the range of % inhibition where the precision 
of the assay is acceptable. However, application of such 
modifications for every single assay is impractical at pre-
sent. The aim of this study was to evaluate the inter-assay 
and inter-laboratory variations using methods which can 
be applied in many laboratories routinely. The minor dif-
ferences between the two laboratories in methods did not 
cause any measurable “laboratory” effect on percent inhi-
bitions. The present work stems from observations from 
a preliminary study where results with 4B7 mAb from 
two additional laboratories were compared. While there 
was an unfortunate loss in stability of the antibody dur-
ing preparation and shipment, the results showed simi-
lar trends in percent inhibition between the labs despite 
several differences in methodology (Yimin Wu, Rhoel 
Dinglasan, personal communication). The approach used 
here will be useful to determine whether any difference in 
SMFA procedure affects SMFA readouts.
Because %TRA plateau at low and high concentrations 
of the test antibody (which gives 0 %TRA and 100 %TRA, 
respectively), the SMFA cannot discriminate between 
doses that fall within these upper or lower plateaus. The 
results of this study indicate that precision of the SMFA 
is very high at (near-) saturated antibody concentrations, 
where the sensitivity to changes in antibody concentra-
tions is low. To reveal any differences in assay sensitivity 
between the two laboratories, IC50 values observed for 
the rat 85RF45.1 and human polyclonal samples were 
compared. For all antibodies tested here, the dose–effect 
relationship fitted well to a Hill equation, concordant 
with the notion that the interaction between an antibody 
and a ligand can be described by equilibrium kinetics 
[31]. The differences in IC50 values between laboratories 
were not larger than the inter-assay differences observed 
within a single laboratory. The SMFA data from this 
study also fitted well with a linear regression when doses 
and %TRA were transformed appropriately [11]. While 
the dose effect was significant, the test site did not sig-
nificantly influence the outcome. Compared to analyses 
that evaluate single doses, the full dose response analyses 
takes into account all data points. This increase in num-
ber of observations is likely to increase precision of the 
measure of inhibition. Moreover, an understanding of 
the dose–effect relationship will guide predictions of the 
minimally required titer to achieve the desired reduction 
in transmission in human SSM-VIMT studies and cam-
paigns. However, to demine the dose–effect relationship, 
each test sample needs to be tested at multiple concen-
trations. Therefore, the best balance between throughput 
of assay and precision/sensitivity needs to be optimized 
on a per study basis.
This study showed large variation in baseline oocyst 
intensities between different feeds (ranging from 4 to 62 
mean oocysts in this study). Standardization of the aver-
age number of oocysts in assay controls would benefit 
from a gametocyte fertility marker, which is lacking at the 
moment. Nevertheless, the data indicate that the relative 
reduction in oocyst intensity (%TRA) can be measured 
reproducibly at higher levels of inhibition when oocyst 
intensity in the controls differed between 4 and 62. A 
recent study conducted at LMVR (repeat assays with 
4B7 mAb and simulations using a zero-inflated negative 
binomial model) also supports that %TRA is independ-
ent from control oocyst intensity in SMFA (mean con-
trol oocyst intensity in the study ranged from 0.1 to 73.7) 
[26]. This study reconfirms that an inter-assay variability 
in the SMFA decreases with increasing percentage inhi-
bition and that variability was demonstrated to be similar 
between different laboratories. While a weaker inhibitory 
activity reported from any laboratory needs to be inter-
preted carefully (unless tested many times or with many 
mosquitoes), results are very reproducible in higher per-
centage inhibition. The SMFAs that are performed at 
the two test sites described here give similar results in 
terms of precision and sensitivity. This is important for 
the screening and development of transmission reducing 
antibodies or compounds, as it alleviates the necessity of 
performing head-to-head analyses in the same assay(s) at 
the same laboratory, and thereby increases the flexibility 
in multi-center vaccine development programs. While 
additional tests are likely to be required when other labo-
ratories participate in multi-centre SMFA evaluations, 
the study design and findings presented in this manu-
script will provide guidance for the additional testing, 
thus supporting future SSM-VIMT development.
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